JP2002501885A5 - - Google Patents

Download PDF

Info

Publication number
JP2002501885A5
JP2002501885A5 JP2000529227A JP2000529227A JP2002501885A5 JP 2002501885 A5 JP2002501885 A5 JP 2002501885A5 JP 2000529227 A JP2000529227 A JP 2000529227A JP 2000529227 A JP2000529227 A JP 2000529227A JP 2002501885 A5 JP2002501885 A5 JP 2002501885A5
Authority
JP
Japan
Prior art keywords
aerosol
surfactant
drug
weight
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000529227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002501885A (ja
Filing date
Publication date
Priority claimed from US09/016,265 external-priority patent/US6086376A/en
Application filed filed Critical
Publication of JP2002501885A publication Critical patent/JP2002501885A/ja
Publication of JP2002501885A5 publication Critical patent/JP2002501885A5/ja
Withdrawn legal-status Critical Current

Links

JP2000529227A 1998-01-30 1998-12-30 微粒子吸入用製剤 Withdrawn JP2002501885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/016,265 US6086376A (en) 1998-01-30 1998-01-30 Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US09/016,265 1998-01-30
PCT/US1998/027922 WO1999038493A1 (en) 1998-01-30 1998-12-30 Microparticle inhalation formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010128713A Division JP2010248206A (ja) 1998-01-30 2010-06-04 微粒子吸入用製剤

Publications (2)

Publication Number Publication Date
JP2002501885A JP2002501885A (ja) 2002-01-22
JP2002501885A5 true JP2002501885A5 (enExample) 2006-02-23

Family

ID=21776235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000529227A Withdrawn JP2002501885A (ja) 1998-01-30 1998-12-30 微粒子吸入用製剤
JP2010128713A Pending JP2010248206A (ja) 1998-01-30 2010-06-04 微粒子吸入用製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010128713A Pending JP2010248206A (ja) 1998-01-30 2010-06-04 微粒子吸入用製剤

Country Status (10)

Country Link
US (1) US6086376A (enExample)
EP (1) EP1051154A1 (enExample)
JP (2) JP2002501885A (enExample)
KR (1) KR20010040402A (enExample)
CN (1) CN1155367C (enExample)
AU (1) AU756464B2 (enExample)
CA (1) CA2319100C (enExample)
IL (1) IL137472A (enExample)
SE (1) SE0002643L (enExample)
WO (1) WO1999038493A1 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
ATE252889T1 (de) 1998-08-19 2003-11-15 Skyepharma Canada Inc Injizierbare wässerige propofoldispersionen
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
HK1042856B (zh) 1998-11-20 2007-07-27 Skyepharma Canada Inc. 可分散的磷脂稳定的微粒
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
DE60020382T2 (de) * 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US6645467B2 (en) * 1999-11-28 2003-11-11 Scientific Development And Research, Inc. Composition and method for decreasing upper respiratory airway resistance
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
EP1337239B2 (en) 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
DK2283818T3 (en) * 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
KR100947409B1 (ko) * 2002-03-01 2010-03-12 키에시 파르마슈티시 엣스. 피. 에이. 포모테롤 초미세 조성물
JP3620842B2 (ja) * 2002-12-25 2005-02-16 孝之 阿部 多角バレルスパッタ装置、多角バレルスパッタ方法及びそれにより形成された被覆微粒子、被覆微粒子の製造方法
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20050121025A1 (en) * 2003-12-04 2005-06-09 Gamard Stephan C.F. Portable gas operating inhaler
TWI262798B (en) * 2003-12-31 2006-10-01 Ind Tech Res Inst Liposome and drug deliver system
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
US8082735B2 (en) * 2005-04-06 2011-12-27 Massachusetts Institute Of Technology Optimized fuel management system for direct injection ethanol enhancement of gasoline engines
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
WO2008152398A2 (en) * 2007-06-14 2008-12-18 Cipla Limited Formulations for inhalation
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CN103228266B (zh) * 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
GB201118232D0 (en) 2011-10-21 2011-12-07 M W Encap Ltd Pharmaceutical composition
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JP6417181B2 (ja) * 2014-10-10 2018-10-31 学校法人神奈川大学 エアゾール作製用乳化組成物、及びエアゾール剤
SG11201705069YA (en) * 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017156380A1 (en) * 2016-03-10 2017-09-14 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US10315836B2 (en) * 2017-10-19 2019-06-11 Matthew James ZABLOSKI Methods, uses, and apparatus for presenting and storing objects
PL3706762T3 (pl) 2017-12-07 2025-02-10 Emory University N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
US20210353650A1 (en) * 2020-05-18 2021-11-18 Cai Gu Huang Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation
WO2025023975A1 (en) * 2023-07-27 2025-01-30 Bard Peripheral Vascular, Inc. Methods for the preparation of phospholipid bilayer carriers

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
GB9002327D0 (en) * 1990-02-02 1990-04-04 Univ Sheffield Optical elements
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
AU658854B2 (en) * 1990-10-18 1995-05-04 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
DE4132677C2 (de) * 1991-10-01 1995-08-24 Braun Melsungen Ag Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ATE171865T1 (de) * 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
JPH08507792A (ja) * 1993-03-17 1996-08-20 ミネソタ マイニング アンド マニュファクチャリング カンパニー ジオール−二酸から誘導される分散助剤を含むエーロゾル配合物
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
BR9604976A (pt) * 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
WO1996032151A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
EP1908488A3 (en) * 1995-04-14 2008-04-16 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation

Similar Documents

Publication Publication Date Title
JP2002501885A5 (enExample)
JP2786493B2 (ja) 医薬エアゾール製剤
JP2915574B2 (ja) 医療用エアロゾル製剤
JP5170789B2 (ja) 喘息治療用の製薬組成物
EP0904056B1 (en) Process and device for inhalation of particulate medicaments
TWI546094B (zh) 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
US5439670A (en) Medicinal aerosol formulations
JP2002530316A (ja) Ｈｆａ２２７およびｈｆａ１３７を含有する製薬学的エアゾル組成物
JP2001501209A (ja) ブデソニドを含有する医療用エアゾル組成物
JPH10510521A (ja) エアゾール処方物用噴射剤混合物
UA70289C2 (uk) Композиція для використання з аерозольним інгалятором, аерозольний інгалятор та спосіб його заповнення
JP2002541183A (ja) 医薬用エアゾール製剤
AU2002313828A1 (en) Pharmaceutical compositions for the treatment of asthma
WO2000000215A1 (en) Particulate delivery systems and methods of use
JP2002501885A (ja) 微粒子吸入用製剤
CN105392471A (zh) 用于呼吸递送三种或更多种活性剂的组合物、方法和系统
AU760537B2 (en) Particulate delivery systems and methods of use
WO1998041191A1 (en) Aerosol preparation
CN114344285A (zh) 改良的可吸入团聚物
CN105106200A (zh) 用于呼吸递送两种或多种活性剂的组合物、方法和系统
NZ243056A (en) Aerosol formulation containing a medicament, tetrafluoroethane and isopropyl myristate
CA2303601A1 (en) Medicinal aerosol formulations